BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 18431378)

  • 1. Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.
    Ortiz A; Oliveira JP; Wanner C; Brenner BM; Waldek S; Warnock DG
    Nat Clin Pract Nephrol; 2008 Jun; 4(6):327-36. PubMed ID: 18431378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
    Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
    Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
    Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
    Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
    Tahir H; Jackson LL; Warnock DG
    J Am Soc Nephrol; 2007 Sep; 18(9):2609-17. PubMed ID: 17656478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease: treatment and diagnosis.
    Rozenfeld PA
    IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fabry disease: angiokeratoma, biomarker, and the effect of enzyme replacement therapy on kidney function.
    Ries M; Schiffmann R
    Arch Dermatol; 2005 Jul; 141(7):904-5; author reply 905-6. PubMed ID: 16027312
    [No Abstract]   [Full Text] [Related]  

  • 11. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.
    Thurberg BL; Fallon JT; Mitchell R; Aretz T; Gordon RE; O'Callaghan MW
    Circulation; 2009 May; 119(19):2561-7. PubMed ID: 19414635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal involvement in Anderson-Fabry disease.
    Sessa A; Meroni M; Battini G; Righetti M; Maglio A; Tosoni A; Nebuloni M; Vago G; Giordano F
    J Nephrol; 2003; 16(2):310-3. PubMed ID: 12774774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease with aortic regurgitation.
    Choi S; Seo H; Park M; Kim J; Hwang S; Kwon K; Her K; Won Y
    Ann Thorac Surg; 2009 Feb; 87(2):625-8. PubMed ID: 19161799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
    Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
    Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enzyme replacement therapy in Fabry's disease].
    Alvarez L; del Pozo C; Trigueros M; Sánchez L; Albero MD; López-Menchero R; Ortega E
    Nefrologia; 2005; 25(3):322-7. PubMed ID: 16053014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fabry disease: a review of current management strategies.
    Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
    QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fabry disease in Italy: first epidemiologic and collaborative study].
    Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
    Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fabry-Anderson disease: current state of knowledge].
    Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
    Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.